Othman Al-Sawaf
Othman Al-Sawaf
Dep I of Internal Medicine, Univ Hosp of Cologne // Francis Crick Institute, UCL Cancer Institute
Verified email at
Cited by
Cited by
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...
New England Journal of Medicine 380 (23), 2225-2236, 2019
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open …
O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ...
The Lancet Oncology 21 (9), 1188-1200, 2020
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ...
The Lancet Respiratory Medicine 9 (5), 522-532, 2021
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
M Hallek, O Al‐Sawaf
American journal of hematology 96 (12), 1679-1705, 2021
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ...
Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017
Nrf2 in health and disease: current and future clinical implications
O Al-Sawaf, T Clarner, A Fragoulis, YW Kan, T Pufe, K Streetz, CJ Wruck
Clinical science 129 (12), 989-999, 2015
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ...
Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ...
The Lancet Oncology 19 (9), 1215-1228, 2018
Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, ...
Journal of Clinical Oncology 39 (36), 4049, 2021
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
O Al-Sawaf, S Robrecht, J Bahlo, AM Fink, P Cramer, J v Tresckow, ...
Leukemia 35 (1), 169-176, 2021
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
AM Fink, J Bahlo, S Robrecht, O Al-Sawaf, A Aldaoud, H Hebart, ...
The Lancet Haematology 4 (10), e475-e486, 2017
Nrf2 augments skeletal muscle regeneration after ischaemia–reperfusion injury
O Al‐Sawaf, A Fragoulis, C Rosen, N Keimes, EA Liehn, F Hölzle, ...
The Journal of pathology 234 (4), 538-547, 2014
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
CD Herling, F Cymbalista, C Groß-Ophoff-Müller, J Bahlo, S Robrecht, ...
Leukemia 34 (8), 2038-2050, 2020
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
P Langerbeins, C Zhang, S Robrecht, P Cramer, M Fürstenau, O Al-Sawaf, ...
Blood, The Journal of the American Society of Hematology 139 (2), 177-187, 2022
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
O Al-Sawaf, E Lilienweiss, J Bahlo, S Robrecht, AM Fink, M Patz, ...
Blood, The Journal of the American Society of Hematology 135 (11), 866-870, 2020
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
J von Tresckow, P Cramer, J Bahlo, S Robrecht, P Langerbeins, AM Fink, ...
Leukemia 33 (5), 1161-1172, 2019
Using DNA sequencing data to quantify T cell fraction and therapy response
R Bentham, K Litchfield, TBK Watkins, EL Lim, R Rosenthal, ...
Nature 597 (7877), 555-560, 2021
Quantitative analysis of minimal residual disease (MRD) shows high rates of undetectable MRD after fixed-duration chemotherapy-free treatment and serves as surrogate marker for …
K Fischer, M Ritgen, O Al-Sawaf, S Robrecht, M Tandon, AM Fink, ...
Blood 134, 36, 2019
Ibrutinib versus placebo in patients with asymptomatic, treatment‐naïve early stage CLL: primary endpoint results of the phase 3 double‐blind randomized CLL12 trial
P Langerbeins, J Bahlo, C Rhein, H Gerwin, P Cramer, M Fürstenau, ...
Hematological Oncology 37, 38-40, 2019
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
O Al-Sawaf, C Zhang, HY Jin, S Robrecht, Y Choi, S Balasubramanian, ...
Nature Communications 14 (1), 2147, 2023
The system can't perform the operation now. Try again later.
Articles 1–20